Testing effectiveness (Phase 2)Study completedNCT02423343
What this trial is testing
Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
Who this might be right for
Solid TumorNon-Small Cell Lung Cancer RecurrentHepatocellular Carcinoma Recurrent
Eli Lilly and Company 41